Strategically Designed Panel for the Optimal Management of Thyroid Nodules. And now, newly added TERT and ALK mutations can reliably help to predict aggressive biological features of thyroid cancer.
Interpace Diagnostics is the only company that offers:
The Federal Employee Health Benefit BCBS Program Adds Approximately 5.3 Million Covered Lives PARSIPPANY, NJ, Nov. 07, 2018 (GLOBE NEWSWIRE) — Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that
Including Participation in the Panel on the Impact of AI and Bioinformatics in Healthcare PARSIPPANY, NJ, Oct. 24, 2018 (GLOBE NEWSWIRE) — Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or
Discussing Methods for Securing Coverage and Reimbursement for New Technologies PARSIPPANY, NJ, Oct. 22, 2018 (GLOBE NEWSWIRE) — Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that the Company has been
Interpace Diagnostics is a registered trademark and business unit of Interpace Biosciences, Inc.™
©2019 Interpace Biosciences, Inc.™ All rights reserved.
